- Home
- ITRG vs ALT Comparison
ITRG vs ALT Comparison
Compare ITRG & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITRG | ALT |
|---|---|---|
| Founded | 1997 | 1997 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.5M | 501.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ITRG | ALT |
|---|---|---|
| Price | $3.50 | $5.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $4.00 | ★ $16.33 |
| AVG Volume (30 Days) | 2.2M | ★ 3.3M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $219,125,000.00 | $20,000.00 |
| Revenue This Year | $709.65 | N/A |
| Revenue Next Year | $36.86 | N/A |
| P/E Ratio | $45.52 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.79 | $2.90 |
| 52 Week High | $3.52 | $10.88 |
Technical Indicators
Market Signals| Indicator | ITRG | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 66.21 | 74.79 |
| Support Level | $2.73 | $4.40 |
| Resistance Level | $3.12 | $4.75 |
| Average True Range (ATR) | 0.23 | 0.29 |
| MACD | 0.05 | 0.10 |
| Stochastic Oscillator | 96.83 | 92.19 |
Price Performance
Historical ComparisonAbout ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.